Stocks
The weight loss wars get heavier
One says pill, one says combo drug.
Follow pharmaceutical company stocks—blockbuster drugs, patent cliffs, pipeline depth, and pricing policy risks affecting pharma valuations.
One says pill, one says combo drug.
That's more bad news for Novo Nordisk.
Will it be enough to turn things around?
Shares exploded over 140% higher.
But Wall Street isn't convinced it will work.
Big Pharma is hunting for its next blockbuster.
Stay up to date on the latest market news with daily analysis of the investing landscape, served up Brew-style.
By subscribing, you accept our Terms & Privacy Policy.